Spearhead Capital Advisors LLC lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.8% in the first quarter, Holdings Channel reports. The firm owned 3,706 shares of the company’s stock after buying an additional 170 shares during the period. Spearhead Capital Advisors LLC’s holdings in CRISPR Therapeutics were worth $452,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in CRSP. Wolff Wiese Magana LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $199,000. Norges Bank purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth $86,215,000. First American Bank acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $204,000. Congress Asset Management Co. MA increased its position in shares of CRISPR Therapeutics by 1.0% in the 4th quarter. Congress Asset Management Co. MA now owns 16,695 shares of the company’s stock valued at $2,556,000 after acquiring an additional 170 shares during the period. Finally, Vigilant Capital Management LLC raised its stake in CRISPR Therapeutics by 157.7% in the 1st quarter. Vigilant Capital Management LLC now owns 773 shares of the company’s stock worth $94,000 after acquiring an additional 473 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.
In other news, Director Bradley J. Phd Bolzon sold 30,374 shares of the business’s stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $132.37, for a total transaction of $4,020,606.38. Following the completion of the transaction, the director now directly owns 57,149 shares of the company’s stock, valued at $7,564,813.13. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 17.10% of the company’s stock.
CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, April 26th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.47) by ($0.04). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. On average, equities analysts predict that CRISPR Therapeutics AG will post -4.97 earnings per share for the current year.
Several brokerages recently weighed in on CRSP. Truist increased their price target on shares of CRISPR Therapeutics from $170.00 to $210.00 in a report on Tuesday, January 12th. JMP Securities started coverage on shares of CRISPR Therapeutics in a research report on Wednesday, March 10th. They set an “outperform” rating and a $160.00 target price for the company. TheStreet downgraded CRISPR Therapeutics from a “c-” rating to a “d” rating in a research report on Wednesday, March 10th. Zacks Investment Research downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating and set a $177.00 target price on the stock. in a research note on Monday, February 1st. Finally, The Goldman Sachs Group decreased their price target on CRISPR Therapeutics from $193.00 to $189.00 and set a “neutral” rating for the company in a report on Wednesday, February 17th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $161.82.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Recommended Story: Index Funds
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.